A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025.

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Van Der Beek offered a reminder that colorectal cancer is one of the most curable types of cancer when it’s caught early and ...

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 30.9% ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Wednesday reported a loss of $99.9 million in its second quarter. The Palo Alto, California-based company said it had a ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...